Welcome to our dedicated page for Zevra Therapeutics SEC filings (Ticker: ZVRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech companies publish some of the most technical disclosures on EDGAR, and Zevra Therapeutics is no exception. R&D expense swings tied to rare-disease trials, updates on FDA orphan-drug designations, and dilution from financing rounds all live inside 10-K, 10-Q, and 8-K forms that regularly top 200 pages. If you have ever typed 鈥渉ow do I read Zevra Therapeutics鈥� 10-K?鈥� this page delivers Zevra Therapeutics SEC filings explained simply.
Stock Titan鈥檚 AI parses every line the moment it hits the tape, then surfaces what matters. Need the latest Zevra Therapeutics quarterly earnings report 10-Q filing? We highlight trial-spend by program and cash runway in plain English. Curious about Zevra Therapeutics insider trading Form 4 transactions before a data release? Get Zevra Therapeutics Form 4 insider transactions real-time alerts. Our platform also tags Zevra Therapeutics 8-K material events explained and turns them into concise summaries, so you can focus on decision-making instead of document hunting.
Drill deeper with our AI-powered tools:
- Zevra Therapeutics annual report 10-K simplified 鈥� see pipeline status, orphan-drug exclusivity timelines, and revenue assumptions in minutes.
- Zevra Therapeutics earnings report filing analysis 鈥� track quarter-over-quarter cash burn and partnership revenue.
- understanding Zevra Therapeutics SEC documents with AI 鈥� tap sectional notes that translate accounting jargon.
- Zevra Therapeutics executive stock transactions Form 4 鈥� monitor how leadership reacts to pivotal trial milestones.
- Zevra Therapeutics proxy statement executive compensation 鈥� decode incentive structures tied to clinical success.
All filings update in real time, are searchable by keyword, and come with exportable data tables鈥攂ecause biotech diligence should be precise, not painful.
Royal Bank of Canada (RY) has filed a preliminary 424(b)(2) pricing supplement for three separate Capped Enhanced Return Buffer Notes maturing 4 August 2027. Each note is linked to a single equity index鈥擭asdaq-100 (NDX), Russell 2000 (RTY) or S&P 500 (SPX)鈥攁nd will be issued in $1,000 denominations on 5 August 2025.
Upside mechanics. If the Final Underlier Value exceeds the Initial Underlier Value, investors receive 150 % of the index return, capped at a Maximum Return set on the trade date (indicative ranges: NDX 24.5-26.5 %, RTY 28-30 %, SPX 20-22 %).
Downside mechanics. A 10 % buffer protects principal as long as the index does not lose more than 10 %. Below that threshold, principal is reduced point-for-point beyond the 10 % loss. Example: a 50 % index decline produces a 40 % note loss ($600 redemption).
Key terms.
- Participation Rate: 150 % (subject to cap)
- Buffer Value: 90 % of initial index level
- Trade Date: 31 Jul 2025 | Valuation Date: 30 Jul 2027
- Maturity: 4 Aug 2027 (2-year term)
- Price to public: 100 % of face; underwriting discount 1 % (dealer concessions up to $10 per $1,000)
- Initial estimated value: $928-$979 (i.e., 92.8-97.9 % of face), below issue price
Risk highlights. The notes pay no coupons, have limited upside due to the cap, and expose investors to 1-for-1 downside beyond the 10 % buffer. They are senior unsecured obligations of Royal Bank of Canada鈥攑ayments depend on the bank鈥檚 credit. The securities are intended to be held to maturity; no exchange listing is planned and secondary liquidity is expected to be thin, with bid-ask spreads and dealer mark-downs likely. The issuer鈥檚 initial estimated value鈥攃alculated using RBC鈥檚 internal funding rate鈥攚ill be lower than the offering price, creating an immediate economic cost to the investor. U.S. tax treatment is uncertain; RBC expects the notes to be treated as prepaid financial contracts.
Investors seeking enhanced, but capped, equity exposure with partial downside protection may find the structure useful; however, the product鈥檚 risk/return trade-off, illiquidity, and issuer credit considerations must be carefully weighed.
Engine Capital and its affiliates have filed Amendment No. 3 to Schedule 13D on 18 June 2025 disclosing an aggregate 9.9 % ownership stake in Civeo Corporation (CVEO).
The filing covers multiple related entities鈥擡ngine Capital, Engine Jet, Engine Lift, Engine Capital Management, Engine Capital Management GP, Engine Investments, Engine Investments II and managing partner Arnaud Ajdler. Collectively, they report beneficial ownership of 1,338,114 common shares out of 13,453,255 shares outstanding as of 25 April 2025. Individual stakes include 1,111,951 shares (8.3 %) held directly by Engine Capital and smaller positions held by the affiliated funds.
Purpose of transaction: The group states that 鈥渢he Board could benefit from the perspective of a highly qualified, independent director.鈥� They are actively engaging鈥攁nd expect to continue engaging鈥攚ith Civeo regarding the potential appointment of such an independent director. No plans for immediate acquisition or disposition of additional shares are disclosed.
Source of funds is identified as working capital (WC) for the limited partnerships and 鈥渙ther鈥� (OO) for the management and general-partner entities. All signatures are dated 18 June 2025 and executed by Arnaud Ajdler in his various representative capacities.
The amendment formalises Engine Capital鈥檚 activist posture without crossing the 10 % threshold that would mandate a Form 13D filing update within ten days. Investors should monitor forthcoming interactions between the activist group and Civeo鈥檚 board, as governance changes or additional share accumulation could follow.
Zevra Therapeutics, Inc. (ZVRA) 鈥� Form 4 filing dated 06/24/2025
The filing discloses an equity transaction by insider Rahsaan W. Thompson, who serves as Chief Legal & Compliance Officer and Secretary. On 06/21/2025, Thompson acquired 66,666 shares of common stock through the settlement of previously granted restricted stock units (RSUs). The transaction is coded 鈥淢,鈥� indicating a conversion of a derivative security rather than an open-market purchase or sale.
Table II shows the RSU award underlying the transaction. The original grant totals 133,334 RSUs. According to the vesting schedule, one-third (66,666 units) vested and converted to common stock on 06/21/2025; the remaining two tranches will vest in equal annual installments, subject to continued service. Following the settlement, Thompson directly holds 66,666 shares of common stock and retains 133,334 unvested RSUs that may convert into an equal number of shares over the next two years.
No price is listed for the RSUs because the grant is equity-settled at no cash cost to the insider. There is no indication of open-market buying or selling, no mention of a 10b5-1 trading plan check-box selection, and no other classes of securities were involved. The filing is routine and does not provide information on company operations, earnings, or strategic initiatives.
FAQ
What is the current stock price of Zevra Therapeutics (ZVRA)?
What is the market cap of Zevra Therapeutics (ZVRA)?
What is the core focus of Zevra Therapeutics Inc?
How does Zevra Therapeutics generate its revenue?
What differentiates Zevra鈥檚 development strategy in the rare disease space?
How is Zevra Therapeutics structured to address complex drug development challenges?
What role do strategic partnerships play in Zevra鈥檚 operations?
How does Zevra Therapeutics ensure its therapies address real patient needs?
